The role of leptin in the etiopathogenesis of anorexia nervosa and bulimia

Original Research Paper

Abstract

Leptin is an adipocyte-derived signal factor (167 amino acid protein) encoded by the ob gene in chromosome 7q31 that regulates eating behaviour via central neuroendocrine mechanisms. It has been shown that serum leptin levels correlate with weight and percentage body fat in normal and obese individuals, but the exact correlation between leptin and body weight in anorexic and bulimic patients has not yet been clarified. We investigated leptin levels in the serum of 58 female subjects aged 15-36 years: 10 with bulimia nervosa (BN); 12 with anorexia nervosa (AN); 12 overweight controls (not BN); 12 weight-reduced controls (not AN); and 12 normal weight controls. The aim of the study was to evaluate the possible correlations between leptin levels and the body mass index (BMI) in all five groups. Our results showed that the serum leptin levels of the bulimic patients were similar to those of the healthy controls, with a positive correlation between leptin and BMI. Although bulimic patients have very bad nutritional behaviour, their leptin levels do not appear altered. Serum leptin was significantly (p<0.001) reduced in the anorexic patients because of the dramatic decrease in adipose mass caused by the nutritional defect, as: is further supported by the significantly (p<0.001) low level of transferrinemia. Our data suggest that, although significantly reduced, serum leptin levels in fasting anorexic patients are non-linearly related to body weight (BMI).

Key words

Serum leptin levels humans BMI anorexia bulimia weight-reduced controls 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Becker A.E., Grinspoon S.K., Klibanski A, Herzog D.B.: Eating disorders. N. Engl. J. Med., 340, 1092–1098, 1999.PubMedCrossRefGoogle Scholar
  2. 2.
    Eiro M., Katoh T. et al.: Use of a proton-pump inhibitor for metabolic disturbances associated with anorexia nervosa. N. Engl. J. Med., 346, 140, 2002.PubMedCrossRefGoogle Scholar
  3. 3.
    Zhang Y., Proenca R., et al.: Positional cloning of the mouse obese gene and its human homologue. Nature, 372, 425–432, 1994.PubMedCrossRefGoogle Scholar
  4. 4.
    Campfield L.A., Smith F.J. et al.: Recombinant mouse OB protein; evidence for a peripheral signal linking adiposity and central neural networks. Science, 269, 546–549, 1995.PubMedCrossRefGoogle Scholar
  5. 5.
    Weigle D.S., Bukowski T.R., Foster D.C., et al.: Recombinant ob protein reduces feeding and body weight in the OB/OB mouse. J. Clin. Invest., 96, 2065–2070, 1995.PubMedCrossRefGoogle Scholar
  6. 6.
    Tartaglia L.A., Dembski M., Weng X., et al.: Identification and expression cloning of a leptin receptor, OB-R. Cell, 83, 1263–1271, 1995.PubMedCrossRefGoogle Scholar
  7. 7.
    Shuldiner A.R., Yang R., et al.: Resistin, obesity, and insulin-resistance. The emerging role of the adipocyte as an endocrine organ. N. Engl. J. Med., 345, 1345–1346, 2001.PubMedCrossRefGoogle Scholar
  8. 8.
    Musso F., Calandra C., Musso R., et al.: Evaluation of leptin protein and human thrombopoietin levels in patients with anorexia nervosa and bulimia. Hematol. J., 1 (suppl.1) abstract, 256, 76, 2001.Google Scholar
  9. 9.
    Musso F., Calandra C., Musso R., et al.: Relationship of human plasma leptin concentration with blood cell parameters in anorexia nervosa and bulimia patients. Hematol. J., 1 (suppl.1) abstract, 266, 76, 2001.Google Scholar
  10. 10.
    Ghilardi N., Skoda R.C.: The leptine receptor activates janus kinase 2 and signals for proliferation in a factor-dependent cell line. Mol. Endocrinol., 11, 393–399, 1997.PubMedCrossRefGoogle Scholar
  11. 11.
    Baumann H., Morella K.K., et al.: The full length leptin receptor has signalling capabilities of interleukin 6-type receptors. Proc. Natl. Acad. Sci. USA, 93, 8374–8378, 1996.PubMedCrossRefGoogle Scholar
  12. 12.
    Stephens T.W., Basinski M., Bristow P.K., et al.: The role of neuropeptide Y in the antiobesity action of the obese gene product. Nature, 377, 530–532, 1995.PubMedCrossRefGoogle Scholar
  13. 13.
    Baj Y., Zhang S., et al.: Obese gene expression alters the ability of 30A5 preadipocytes to respond to lipogenic hormones. J. Biol. Chem., 271, 13939–13942, 1996.CrossRefGoogle Scholar
  14. 14.
    Cohen B., Novick D., Rubinstein M.: Modulation of insulin activities by leptin. Science, 274, 1185–1188, 1996.PubMedCrossRefGoogle Scholar
  15. 15.
    Gainsford T., Wilson T.A., Metcalf D., et al.: Leptin can induce proliferation, differentiation, and functional activation of hemopoietic cells. Proc. Natl. Acad. Sci. USA, 93, 14564–14568, 1996.PubMedCrossRefGoogle Scholar
  16. 16.
    Shimabukuro M., Koyama K., Chen G., et al.: Direct antidiabetic effect of leptin through triglyceride depletion of tissues. Proc. Natl. Acad. Sci. USA, 94, 4637–4641, 1997.PubMedCrossRefGoogle Scholar
  17. 17.
    Caro J., Sinha M.K., Kolacziynski L.W., Zhang P.L., Considine R.V.: Leptin: the tale of an obesity gene. Diabetes, 45, 1455–1462, 1996.PubMedCrossRefGoogle Scholar
  18. 18.
    Caro J.F., Kolacziynski J.W., Nyce M.R., et al.: Decreased cerebrospinal fluid/serum leptin ratio in obesity: a possible mechanism for leptin resistance. Lancet, 348, 159–161, 1996.PubMedCrossRefGoogle Scholar
  19. 19.
    Maffei M., Halaas J., Ravussin E., et al.: Leptin levels in human and rodent: measurement of plasma leptin and OB RNA in obese and weight-reduced subjects. Nature Med., 1, 1155–1161, 1995.PubMedCrossRefGoogle Scholar
  20. 20.
    Ahima R.S., Prabakaran D., Mantzoros C., et al.: Role of leptin in the neuroendocrine response to fasting. Nature, 382, 250–252, 1996.PubMedCrossRefGoogle Scholar
  21. 21.
    Thompson F.E., Byers T.: Dietary assessment resources manual. J. Nutr. 124, 2245S–2317S, 1994.PubMedGoogle Scholar
  22. 22.
    Manson J.E., Stampfer M.J., Hennekens C.H., Willett W.C.: Body weight and longevity: a reassessment. JAMA 257, 353–358, 1987.PubMedCrossRefGoogle Scholar
  23. 23.
    Calle E.E., et al.: Body mass index and mortality in a prospective cohort of U.S. adults. N. Engl. J. Med., 341, 1097–1104, 1999.PubMedCrossRefGoogle Scholar
  24. 24.
    Report of a WHO expert committee: Physical status: the use and interpretation of anthropometry. WHO Tech. Rep. Ser. 854, 1–452, 1995.Google Scholar
  25. 25.
    American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders (DSM IV) Washington, DC, APA, 1994.Google Scholar
  26. 26.
    Garner D.M.: Professional Manual Eating Disorders Inventory, II Odessa, FL. Psychological assessment resources, 1990.Google Scholar
  27. 27.
    Calandra C., Gulino V. Inserra L., Giuffrida A.: The use of citalopram in an integrated approach to the treatment of eating disorders: An open study. Eat. Weight Disord., 4, 207–210, 1999.PubMedGoogle Scholar
  28. 28.
    Gendall K. A., Bulik C. M., Sullivan P.F., Joyce P.R., McIntosh V.V., Carter F.A.: Body weight in bulimia nervosa. Eat. Weight Disord., 4, 157–164, 1999.PubMedGoogle Scholar
  29. 29.
    Eckert E.D., Pommeroy C. et al.: Leptin in anorexia nervosa. J. Clin. Endocrinol. Metab., 83, 791–795, 1997.CrossRefGoogle Scholar
  30. 30.
    Hebebrand J., Vanderheyden J., Devos R., et al.: Plasma concentration of obese protein in anorexia nervosa. Lancet, 346, 1624–1625, 1995.PubMedCrossRefGoogle Scholar
  31. 31.
    Grinspoon S., Gullick T., Askari H., et al.: Serum leptin levels in women with anorexia nervosa. J. Clin. Endocrinol. Metab., 81, 3861–3863, 1996.PubMedCrossRefGoogle Scholar
  32. 32.
    Rosenbaum M., Nicolson M., Hirsch J., et al.: Effects of gender, body composition and menopause on plasma concentrations of leptin. J. Clin. Endocrinol. Metab., 81, 3424–3427, 1996.PubMedCrossRefGoogle Scholar
  33. 33.
    Argente J., Barris V., et al.: Leptin plasma levels in healthy Spanish children and adolescents, children with obesity and adolescents with anorexia and bulimia nervosa. J. Pediatr., 22, 833–838, 1997.Google Scholar
  34. 34.
    Sorbi S., Nacmias B., et al.: 5-HT2A promoter polymorphism in anorexia nervosa. Lancet, 351, 1785–1786, 1998.PubMedCrossRefGoogle Scholar
  35. 35.
    Fulton S., Woodside B., Shizgal P. et al.: Modulation of brain reward circuitry by Leptin. Science, 287, 125–128, 2000.PubMedCrossRefGoogle Scholar
  36. 36.
    Maffei M., Halaas J., Ravussin E., et al.: Leptin levels in human and rodent: measurement of plasma leptin and OB RNA in obese and weightreduced subjects. Nature Med., 1, 1155–1161, 1995.PubMedCrossRefGoogle Scholar
  37. 37.
    Halaas J.L., Gajiwala K.S., Maffei M., et al.: Weight-reducing effects of the plasma protein encoded by the obese gene. Science, 269, 543–546, 1995.PubMedCrossRefGoogle Scholar
  38. 38.
    Pelleymounter M.A., Cullen M.J., Baker M.B., et al.: Effects of the obese gene product on body weight regulation in the ob/ob mice. Science, 269, 540–543, 1995.PubMedCrossRefGoogle Scholar
  39. 39.
    Farooqi I.S., Jebb S.A., Langmack G., et al.: Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N. Engl. J. Med., 341, 879–883, 1999.PubMedCrossRefGoogle Scholar

Copyright information

© Editrice Kurtis 2003

Authors and Affiliations

  1. 1.Department of Medical and Specialist Sciences, Psychiatric DivisionUniversity of Catania, Azienda PoliclinicoCataniaItaly
  2. 2.Institute of Hematology-Hemophilia and Thrombosis CentreUniversity of Catania, Azienda Vittorio Emanuele, Ferrarotto and S. BambinoCataniaItaly

Personalised recommendations